We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Augmented SirT1 Activity Could Protect Against Osteoarthritis

By LabMedica International staff writers
Posted on 07 Dec 2011
Maintaining the activity of the enzyme SirT1 was suggested as a possible new approach to preventing or treating osteoarthritis (OA), a degenerative cartilage disease that affects millions of people around the world.

SirT1 is a histone deacetylase involved in numerous critical cell processes including DNA repair and apoptosis. More...
Previous studies have shown that exposing human osteoarthritic chondrocytes (cartilage cells) to the cytokine TNFalpha generated a stable and enzymatically inactive 75 kDa form of SirT1 (75SirT1) via cathepsin B-mediated cleavage.

Because 75SirT1 was resistant to further degradation, investigators at the Hebrew University of Jerusalem (Israel) assumed it played a distinct role in osteoarthritis (OA) pathology, which they hoped to identify in a study that was published in the October 10, 2011, online edition of the journal Arthritis and Rheumatism.

Over the course of the study OA and normal human chondrocytes were analyzed for the presence of cathepsin B and 75SirT1. Confocal imaging of SirT1 monitored its subcellular trafficking following TNFalpha stimulation.

Results showed that that 75SirT1 was exported to the cytoplasm and colocalized with the mitochondrial membrane. Consistently, immunoprecipitation and immunoblot analyses revealed that 75SirT1 was enriched in mitochondrial extracts and associated with cytochrome C, following TNFalpha stimulation. Preventing nuclear export of 75SirT1 or reducing levels of SirT1 and 75SirT1 augmented chondrocyte apoptosis in the presence of TNFalpha. Cathepsin B and 75SirT1 were elevated in OA as compared to normal chondrocytes. Additional analyses showed that normal human chondrocytes exposed to OA-derived synovial fluid generated the 75SirT1 fragment.

The results indicated that 75SirT1 promoted chondrocyte survival following exposure to proinflammatory cytokines such as TNFalpha. Drug therapies directed at boosting SirT1 production have the potential to retard or reverse OA.

“Developing a combined strategy for diagnosis and treatment, based on these data, could provide an efficient alternative for joint replacement surgery and enable susceptible individuals to experience a better quality of life for years to come,” said senior author Dr. Mona Dvir-Ginzberg, lecturer in the Institute of Dental Sciences at the Hebrew University of Jerusalem.

Related Links:
Hebrew University of Jerusalem



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gel Cards
DG Gel Cards
New
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Insights into sarcomatoid renal cell carcinoma point to broader use of common immunotherapies (Photo courtesy of Salgia NJ et al., Cancer Cell, 2025)

Novel Gene Signature Predicts Immunotherapy Response in Advanced Kidney Cancers

Sarcomatoid renal cell carcinoma (sRCC) is a rare, aggressive form of kidney cancer comprising about 5% of cases and is typically diagnosed at late stages. Resistant to most therapies, it has shown unusually... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.